Insider Selling: Cryoport, Inc. (NASDAQ:CYRX) CFO Sells 1,659 Shares of Stock

Cryoport, Inc. (NASDAQ:CYRX) CFO Robert Stefanovich sold 1,659 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $10,435.11. Following the transaction, the chief financial officer now directly owns 191,419 shares of the company’s stock, valued at $1,204,025.51. The trade was a 0.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Robert Stefanovich also recently made the following trade(s):

• On Monday, March 10th, Robert Stefanovich sold 1,256 shares of Cryoport stock. The shares were sold at an average price of $4.88, for a total transaction of $6,129.28.

Cryoport Price Performance

Shares of CYRX traded down $0.32 during mid-day trading on Tuesday, reaching $6.17. The stock had a trading volume of 728,831 shares, compared to its average volume of 534,310. The firm has a market cap of $307.94 million, a price-to-earnings ratio of -1.83 and a beta of 1.67. Cryoport, Inc. has a 12 month low of $4.58 and a 12 month high of $20.11. The business has a fifty day moving average of $6.98 and a 200 day moving average of $7.43. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70.

Cryoport (NASDAQ:CYRX) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). The firm had revenue of $59.53 million during the quarter, compared to the consensus estimate of $58.71 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same quarter in the previous year, the company earned ($0.29) earnings per share. Equities analysts predict that Cryoport, Inc. will post -0.99 EPS for the current year.

Hedge Funds Weigh In On Cryoport

A number of hedge funds have recently modified their holdings of the company. Cadian Capital Management LP boosted its position in shares of Cryoport by 14.1% in the fourth quarter. Cadian Capital Management LP now owns 4,927,027 shares of the company’s stock worth $38,332,000 after purchasing an additional 609,021 shares during the period. Millennium Management LLC boosted its position in shares of Cryoport by 11.0% during the fourth quarter. Millennium Management LLC now owns 4,139,869 shares of the company’s stock worth $32,208,000 after acquiring an additional 409,353 shares during the last quarter. Fred Alger Management LLC boosted its position in shares of Cryoport by 49.9% during the third quarter. Fred Alger Management LLC now owns 2,698,768 shares of the company’s stock worth $21,887,000 after acquiring an additional 898,481 shares during the last quarter. Thematics Asset Management boosted its position in shares of Cryoport by 176.2% during the third quarter. Thematics Asset Management now owns 1,705,000 shares of the company’s stock worth $13,828,000 after acquiring an additional 1,087,800 shares during the last quarter. Finally, Deutsche Bank AG boosted its position in shares of Cryoport by 0.9% during the fourth quarter. Deutsche Bank AG now owns 1,397,121 shares of the company’s stock worth $10,870,000 after acquiring an additional 12,864 shares during the last quarter. 92.90% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on CYRX. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 target price on shares of Cryoport in a report on Wednesday, March 5th. Guggenheim began coverage on shares of Cryoport in a report on Thursday, December 19th. They set a “buy” rating and a $11.00 target price for the company. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Cryoport currently has a consensus rating of “Moderate Buy” and an average price target of $11.50.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.